Reminder of BOPA SACT Verification Passport Grandparenting Deadline

Dear member,

 

As of the beginning of this month, we have 139 registered sites and 1,600 users subscribed to the SACT verification passport.
This is a fabulous uptake and we appreciate everyone being so engaged.
We hope you find the resource user friendly and beneficial to training and practice.

A reminder that the “Grandparenting Clause” will be available until November 30th 2024, 13-months from the “go-live” as per the Passport Set up and User Guide.

This is extended to June 30th 2025 for those completing the paediatric section, as this was launched later than the adult content.

We encourage all staff who intend to grandparent themselves within the Passport, please do so prior to this deadline, as beyond this, the grandparenting function will no longer be available.

As always, we welcome feedback on your experience with the Passport.
Please contact [email protected] for clinical queries regarding the Passport and contact [email protected] for technical queries surrounding the app.

 

Best Wishes,

BOPA Passport Pillar

Latest News

By BOPA Research Committee on 27th April 2025

SURVEY: Understanding Clinicians’ perceptions of a Decision Support tool for Lung Cancer Treatment

Dear BOPA member, Tarini Deleep and Dr Pinkie Chambers from University College London are developing a risk prediction model to help identify patients with incurable Non Small Cell Lung Cancer,…

Read article
By BOPA on 27th April 2025

Further monographs for use of immunosuppressants in Immune-related adverse events (irAEs)

Earlier this year the BOPA Immunotherapy Group wrote, and published, four monographs to help health care professionals care for patients with immune-related adverse events. As a group we are pleased…

Read article
By BOPA Committee on 27th April 2025

Women for Oncology UK Spring Webinar

The Spring webinar for Women for Oncology UK is on the 16th May, to sign up click the link below. Women For Oncology UK Spring Webinar Tickets, Wed 14 May…

Read article
By BOPA Executive Committee on 25th April 2025

NICE TA: Ribociclib with an aromatase inhibitor can be used as an option for the adjuvant treatment of hormone receptor-positive, HER2-negative, early breast cancer at high risk of recurrence in adults.

BOPA have been involved with the following NICE TA: Ribociclib with an aromatase inhibitor can be used as an option for the adjuvant treatment of hormone receptor-positive, HER2-negative, early breast cancer…

Read article